


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31200236</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1768-3254</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>178</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>May</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of medicinal chemistry</Title>
                <ISOAbbreviation>Eur J Med Chem</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tetrazole hybrids with potential anticancer activity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>341-351</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0223-5234(19)30489-1</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2019.05.071</ELocationID>
            <Abstract>
                <AbstractText>Cancer is one of the main causes of death throughout the world. The anticancer agents are indispensable for the treatment of various cancers, but most of them currently on the market are not specific, resulting in series of side effects of chemotherapy. Moreover, the emergency of drug-resistance towards cancers has already increased up to alarming level in the recent decades. Therefore, it's imperative to develop novel anticancer candidates with excellent activity against both drug-susceptible and drug-resistant cancers, and low toxicity as well. Tetrazole is the bioisoster of carboxylic acid, and its derivatives demonstrated promising anticancer activity. Hybridization of tetrazole with other anticancer pharmacophores may provide novel candidates with anticancer potency. The present review described the anticancer activity of tetrazole hybrids, and the structure-activity relationship (SAR) is also discussed to provide an insight for rational designs of tetrazole anticancer candidates with higher efficiency.</AbstractText>
                <CopyrightInformation>Copyright Â© 2019 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jingyu</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pharmacy College, Henan University of Chinese Medicine, 450046, Zhengzhou, PR China. Electronic address: jyzhang2004@126.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Su</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pharmacy College, Henan University of Chinese Medicine, 450046, Zhengzhou, PR China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ba</LastName>
                    <ForeName>Yanyan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pharmacy College, Henan University of Chinese Medicine, 450046, Zhengzhou, PR China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Zhi</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Huanghuai University, College of Chemistry and Pharmaceutical Engineering, Zhumadian, PR China. Electronic address: chemorgchem@126.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Eur J Med Chem</MedlineTA>
            <NlmUniqueID>0420510</NlmUniqueID>
            <ISSNLinking>0223-5234</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Anticancer activity</Keyword>
            <Keyword MajorTopicYN="N">Hybrid compounds</Keyword>
            <Keyword MajorTopicYN="N">Structure-activity relationship</Keyword>
            <Keyword MajorTopicYN="N">Tetrazole</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31200236</ArticleId>
            <ArticleId IdType="pii">S0223-5234(19)30489-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejmech.2019.05.071</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

